JP2020531581A - 緑内障を治療するためのWnt5aの調節 - Google Patents
緑内障を治療するためのWnt5aの調節 Download PDFInfo
- Publication number
- JP2020531581A JP2020531581A JP2020531558A JP2020531558A JP2020531581A JP 2020531581 A JP2020531581 A JP 2020531581A JP 2020531558 A JP2020531558 A JP 2020531558A JP 2020531558 A JP2020531558 A JP 2020531558A JP 2020531581 A JP2020531581 A JP 2020531581A
- Authority
- JP
- Japan
- Prior art keywords
- wnt5a
- inhibitor
- eye
- formulation
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000010412 Glaucoma Diseases 0.000 title claims abstract description 20
- 101150109862 WNT-5A gene Proteins 0.000 title claims description 43
- 102000043366 Wnt-5a Human genes 0.000 title claims description 43
- 108700020483 Wnt-5a Proteins 0.000 title claims description 41
- 230000004410 intraocular pressure Effects 0.000 claims abstract description 42
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 238000009472 formulation Methods 0.000 claims abstract description 13
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 9
- 229940121694 Wnt5A inhibitor Drugs 0.000 claims abstract description 6
- 108020004459 Small interfering RNA Proteins 0.000 claims description 28
- 239000003112 inhibitor Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 14
- 239000007924 injection Substances 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 13
- 239000003889 eye drop Substances 0.000 claims description 11
- 210000002159 anterior chamber Anatomy 0.000 claims description 8
- 150000003384 small molecules Chemical class 0.000 claims description 8
- 229940012356 eye drops Drugs 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 230000002452 interceptive effect Effects 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 230000003139 buffering effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 abstract 1
- 239000004055 small Interfering RNA Substances 0.000 description 21
- 230000000694 effects Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000001742 aqueous humor Anatomy 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 210000003994 retinal ganglion cell Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 101000804792 Homo sapiens Protein Wnt-5a Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 238000012014 optical coherence tomography Methods 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 2
- 206010011033 Corneal oedema Diseases 0.000 description 2
- 102000013814 Wnt Human genes 0.000 description 2
- 108050003627 Wnt Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 201000004778 corneal edema Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 238000011555 rabbit model Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 101100264065 Danio rerio wnt5b gene Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 230000004509 aqueous humor production Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 102000052779 human WNT5A Human genes 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000035168 lymphangiogenesis Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 229940100655 ophthalmic gel Drugs 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 229940100654 ophthalmic suspension Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001585 trabecular meshwork Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
緑内障は、米国国内で300万人を超える人々、世界全体では6000万人が罹患している大きな健康問題の1つである。2040年には、世界全体で1億1180万人が緑内障に罹患すると推定されている。緑内障の主要な危険因子の1つとして、眼圧上昇(IOP)が挙げられる。眼圧上昇は視神経に障害を与える可能性があり、治療を行わなければ、永久的に失明することもある。現在、緑内障を治癒させる方法はない。既存の点眼薬または経口薬は、効果が限られており、多くの副作用を伴う。また、手術は、瘢痕化や線維化が生じて奏功しないことも多い。
Claims (10)
- 緑内障または病因性眼圧を治療する方法であって、治療を必要とする眼にWnt5a阻害薬を局所投与する工程を含む方法。
- 前記投与工程が、点眼剤による送達、または前房内注射、結膜下注射もしくは硝子体内注射による送達を含む、請求項1の方法。
- 前記阻害薬が、抗体、siRNA、低分子干渉ペプチドおよび低分子阻害剤から選択される、請求項1または2の方法。
- 前記投与が外用であり、前記阻害薬が、外用眼科用のゲル剤、軟膏剤、懸濁剤または液剤の形態で投与される、請求項1、2または3の方法。
- 緑内障または病因性眼圧を治療するための、単位剤形の形態であるWnt5a特異的阻害薬の眼科用製剤であって、該Wnt5a特異的阻害薬が、抗体、siRNA、低分子干渉ペプチドおよび低分子阻害剤から選択される、眼科用製剤。
- 外用眼科用のゲル剤、軟膏剤、懸濁剤または液剤の形態である、請求項5の製剤。
- 前記剤形が、前記阻害薬を含有するコンタクトレンズ、点眼剤、デポ剤またはボーラス剤である、請求項5または6の製剤。
- 点眼剤ディスペンサーに充填されている、請求項5、6または7の製剤。
- 前房内注射用、結膜下注射用または硝子体内注射用のシリンジに充填されている、請求項5、6、7または8の製剤。
- 眼への直接的な外用による送達に適した添加剤および特性をさらに含み、該添加剤および該特性が、眼科用に適した透明性、pH緩衝性、等張性、粘性、安定性および無菌性からなる群から選択される、請求項5、6、7、8または9の製剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023076047A JP2023099171A (ja) | 2017-08-20 | 2023-05-02 | 緑内障を治療するためのWnt5aの調節 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762547854P | 2017-08-20 | 2017-08-20 | |
US62/547,854 | 2017-08-20 | ||
PCT/US2018/046578 WO2019040311A1 (en) | 2017-08-20 | 2018-08-14 | MODULATION OF WNT5A TO TREAT GLAUCOMA |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023076047A Division JP2023099171A (ja) | 2017-08-20 | 2023-05-02 | 緑内障を治療するためのWnt5aの調節 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020531581A true JP2020531581A (ja) | 2020-11-05 |
JP7299889B2 JP7299889B2 (ja) | 2023-06-28 |
Family
ID=65439234
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020531558A Active JP7299889B2 (ja) | 2017-08-20 | 2018-08-14 | 緑内障を治療するためのWnt5aの調節 |
JP2023076047A Pending JP2023099171A (ja) | 2017-08-20 | 2023-05-02 | 緑内障を治療するためのWnt5aの調節 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023076047A Pending JP2023099171A (ja) | 2017-08-20 | 2023-05-02 | 緑内障を治療するためのWnt5aの調節 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20200157158A1 (ja) |
EP (1) | EP3668487A4 (ja) |
JP (2) | JP7299889B2 (ja) |
KR (1) | KR20200042912A (ja) |
CN (4) | CN117159718A (ja) |
WO (1) | WO2019040311A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022266270A1 (en) * | 2021-06-18 | 2022-12-22 | The Regents Of The University Of California | Treatment of Glaucoma by Neuroprotection |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003086334A1 (fr) * | 2002-04-17 | 2003-10-23 | Taisho Pharmaceutical Co., Ltd. | Produit tonique pour la pousse de cheveux |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2729889A1 (en) * | 2000-02-29 | 2001-09-07 | Alcon, Inc. | Screening method for frizzled related proteins agonists and antagonists |
KR100881058B1 (ko) * | 2007-07-06 | 2009-01-30 | 부산대학교 산학협력단 | Wnt5a 단백질의 억제제를 포함하는 신경교아종 치료및 예방용 조성물 |
WO2012158910A2 (en) * | 2011-05-18 | 2012-11-22 | The Regents Of The University Of California | Compositions and methods for treating retinal diseases |
EP2554662A1 (en) * | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
-
2018
- 2018-08-14 KR KR1020207007598A patent/KR20200042912A/ko not_active Application Discontinuation
- 2018-08-14 CN CN202311355500.2A patent/CN117159718A/zh active Pending
- 2018-08-14 WO PCT/US2018/046578 patent/WO2019040311A1/en active Application Filing
- 2018-08-14 EP EP18847365.6A patent/EP3668487A4/en active Pending
- 2018-08-14 JP JP2020531558A patent/JP7299889B2/ja active Active
- 2018-08-14 CN CN202311355449.5A patent/CN117159463A/zh active Pending
- 2018-08-14 CN CN201880052621.0A patent/CN111132664A/zh active Pending
- 2018-08-14 CN CN202311355468.8A patent/CN117379543A/zh active Pending
-
2020
- 2020-01-26 US US16/752,677 patent/US20200157158A1/en not_active Abandoned
-
2023
- 2023-05-02 JP JP2023076047A patent/JP2023099171A/ja active Pending
- 2023-11-28 US US18/522,141 patent/US20240124538A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003086334A1 (fr) * | 2002-04-17 | 2003-10-23 | Taisho Pharmaceutical Co., Ltd. | Produit tonique pour la pousse de cheveux |
Non-Patent Citations (1)
Title |
---|
INVEST OPHTHALMOL VIS SCI, 2013, VOL. 54, PP. 6502-9509, JPN6022021984, ISSN: 0004793491 * |
Also Published As
Publication number | Publication date |
---|---|
EP3668487A1 (en) | 2020-06-24 |
CN117379543A (zh) | 2024-01-12 |
EP3668487A4 (en) | 2020-08-26 |
US20240124538A1 (en) | 2024-04-18 |
JP7299889B2 (ja) | 2023-06-28 |
CN117159718A (zh) | 2023-12-05 |
US20200157158A1 (en) | 2020-05-21 |
JP2023099171A (ja) | 2023-07-11 |
KR20200042912A (ko) | 2020-04-24 |
CN111132664A (zh) | 2020-05-08 |
WO2019040311A1 (en) | 2019-02-28 |
CN117159463A (zh) | 2023-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma | |
AU2015257651B2 (en) | Compounds for treating ophthalmic diseases and disorders | |
JP2017514917A5 (ja) | ||
Doyle et al. | IL-18 immunotherapy for neovascular AMD: tolerability and efficacy in nonhuman primates | |
US20080287915A1 (en) | Tissue engineering system with scleral lens | |
US20070093461A1 (en) | Effect of Loteprednol etabonate on vascular dysfunction | |
Yu-Wai-Man et al. | The role of the MRTF-A/SRF pathway in ocular fibrosis | |
US20240124538A1 (en) | Modulation of Wnt5a to Treat Glaucoma | |
Lazreg et al. | Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications | |
Yamaguchi et al. | Rho-kinase/ROCK as a potential drug target for vitreoretinal diseases | |
Raychaudhuri et al. | Tissue transglutaminase elevates intraocular pressure in mice | |
Kuerten et al. | Transplantation of PEDF-transfected pigment epithelial cells inhibits corneal neovascularization in a rabbit model | |
Irani et al. | An Anti–VEGF-B Antibody Fragment Induces Regression of Pre-Existing Blood Vessels in the Rat Cornea | |
US20080070855A1 (en) | Treatment with anti-VEGF agents to prevent postoperative inflammation and angiogenesis in normal and diseased eyes | |
WO2009089399A2 (en) | Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection | |
JP2022523321A (ja) | 緑内障の新規治療法 | |
Bock et al. | Corneal Angiogenesis and Lymphangiogenesis | |
Bleau et al. | Managing intraocular pressure: Innovation in glaucoma management | |
Testi et al. | Treatment of Uveitic Macular Edema | |
US20240035033A1 (en) | Prevention and treatment of age-related macular degeneration through suppression of cathepsin s expression | |
Martínez et al. | Preclinical development of RNAi-inducing oligonucleotide therapeutics for eye diseases | |
Alharfy et al. | Role of Anti-VEGF (Bevacizumab) in Management of Neovascular Glaucoma: A Review | |
WO2023149420A1 (ja) | 近視を予防または治療するための方法および組成物 | |
Weng et al. | Intravitreal aflibercept for rubeosis iridis secondary to proliferative diabetic retinopathy | |
Joseph | Intravitreal injections: A brief note |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210524 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221031 |
|
A603 | Late request for extension of time limit during examination |
Free format text: JAPANESE INTERMEDIATE CODE: A603 Effective date: 20221031 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230131 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230502 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230515 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230613 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230616 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7299889 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |